Vivisum Partners Publishes Strategic Analysis on the Ulcerative Colitis Marketplace
Among branded ulcerative colitis treatments, 84% of US gastroenterologists expect Zeposia to see an increase in prescription volume over the next 12 months, according to new research on the ulcerative colitis marketplace published by Vivisum Partners. Vivisum Partners has just published its... - October 25, 2022
New Market Insights on the Best MS Treatment Published by Vivisum Partners
What’s the best MS treatment according to neurologists? The question of how to assess the ideal drug to treat multiple sclerosis is difficult to answer. Neurologists determine which clinical attributes take higher priority for each patient. Vivisum Partners, LLC, a market research firm in... - October 24, 2022
Vivisum Partners' Research Finds New Ulcerative Colitis Drugs Provide Excitement to Gastroenterologists
Newly published research found that several new ulcerative colitis drugs currently in development are providing excitement among gastroenterologists eager to add additional medicines to their current treatment options. Based on a market analysis from Vivisum Partners, a market research and brand... - October 08, 2022